Frenz Ohm

Dr. Frenz Ohm

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2022 in Life
Verified
Journal Article
Open access
PDF file
NKNatalia Kirsten
Natalia Kirsten
FOFrenz Ohm
Frenz Ohm
KGKathrin Gehrdau
Kathrin Gehrdau
GGGefion Girbig
Gefion Girbig
BSBrigitte Stephan
Brigitte Stephan
MAMatthias Augustin
Matthias Augustin
Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.

12 January 2024 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CBChristine Blome
Christine Blome
LHLennart Hülswitt
Lennart Hülswitt
AMAnna Meineke
Anna Meineke
MAMatthias Augustin
Matthias Augustin
FOFrenz Ohm
Frenz Ohm
TJToni Maria Janke
Toni Maria Janke
Background: Topical agents are an essential component of psoriasis therapy. Objectives: To develop a new version of the patient-reported Patient Benefit Index assessing the importance and achievement of treatment goals in topical psoriasis therapy in adult patients (PBI-TOP). Methods: Through semi-structured interviews, focus groups and free-text questionnaires, patients reported their needs in topical treatment. Based on qualitative content analysis, items were developed by a consensus group and were refined in cognitive debriefing interviews. A pilot validation assessed the PBI-TOP and convergent criteria [Dermatology Life Quality Index (DLQI); Psoriasis Area and Severity Index (PASI); affected Body Surface Area (BSA)]. Results: Thirty patients (26–72 years, mean 47; 60% male) reported various treatment goals relating to the themes ‘effectiveness’ and ‘characteristics of the preparation’. Twenty patients took part in cognitive debriefings (22–84 years, mean 50.6, 50% male). There were 154 patients who participated in the pilot validation (18–85 years, mean 46.9, 63.6% male). An importance-weighted total score on overall effectiveness and three subscales based on exploratory factor analysis were defined: effectiveness on symptoms, effectiveness on quality of life (QoL), and characteristics of the preparation. All scores showed excellent internal consistency (α > 0.9). The global effectiveness score correlated significantly with DLQI (r = –0.41), PASI (r = –0.32) and BSA (r = –0.22). The effectiveness subscales (symptoms; QoL) correlated significantly with DLQI (r = –0.41; –0.32) and PASI (r = –0.27; –0.33). The score on characteristics of the preparation correlated significantly with the DLQI (r = –0.34). Conclusions: The PBI-TOP showed good feasibility and favourable psychometric characteristics in this pilot validation.

12 August 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
KHKristina Hagenström
Kristina Hagenström
KMKatharina Müller
Katharina Müller
FOFrenz Ohm
Frenz Ohm
MAMatthias Augustin
Matthias Augustin
Background and objectives Data on the population-based epidemiology of hyperhidrosis (HH) are scarce. This study investigated the epidemiology and healthcare of HH in Germany. Design and setting Claims data of adult persons insured by a German statutory health insurance (DAK-Gesundheit) between 2016 and 2020 were analysed. Included were persons aged 18 years and older with a diagnosis of HH (confirmed inpatient or outpatient diagnosis in the observation year) who were continuously insured. Following outcomes were measured: prevalence and incidence rates, severity of hyperhidrosis and inpatient and outpatient care by a group of specialists. Results In 2020, 0.70% of insured adults were confirmed to have HH (mean age 59.5 years, SD 18.9, 61.6% female), with 9.24% having a ‘localised’ form, 8.65% a ‘generalised’ form and 84.80% an ‘unspecified’ form. 0.04% of the total population had a severe form. The incidence was 0.35%. Localised HH was more common in younger age groups (18 to <30 years), while older age groups (70 to <80 years) were significantly more likely to suffer from generalised HH. Systemic anticholinergics were used in 4.55%, and botulinum toxin injection therapy in 0.81%. General practitioners were most frequently involved in care. Inpatient stays due to HH were very rare, with 0.14% in 2019 and 0.04% in 2020. Conclusion Multisource data analysis connecting primary and secondary data will be needed for a complete picture of the healthcare and epidemiology of HH.